Cytek Biosciences, Inc. (CTKB): M&A transaction — Cytek Biosciences completes $46.5M acquisition of Luminex flow cytometry assets

Cytek Biosciences, Inc.

Closed acquisition of Luminex's flow cytometry and imaging business (Amnis, CellStream, Guava, Muse brands) on Feb 28, 2023.
Purchase price approximately $46.5 million in cash, subject to customary adjustments at closing.
Company assumed certain liabilities of the acquired business.
Financial statements and pro forma information to be filed within 71 days after this 8-K.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 1.0

Cytek Biosciences, Inc. completed an acquisition involving Luminex Corporation for approximately $46.5 million in cash (closed 2023-02-28).

Action: acquisition
Counterparty: Luminex Corporation
Consideration: approximately $46.5 million in cash
Closing: 2023-02-28

Exact text from the filing

under the Purchase Agreement. Pursuant to the Purchase Agreement, as consideration for the FCI Acquisition, the Company paid an aggregate purchase price of approximately $46.5 million in cash, subject to certain customary adjustments at closing, and assumed certain liabilities of the Business. The foregoing description of the FCI Acquisition and the Purchase

View on SEC.gov

Browse all m&a transactions →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-052702

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.